Insiders · ELTX

ELTX insider transactions

Elicio Therapeutics Inc. (ELTX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ELTX insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Elicio Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Julian AdamsDirector, since June 2023
• Carol Gail AsheDirector, since June 2023
• Yekaterina ChudnovskyDirector, 10% owner, since June 2023+$7.05M
• Robert R RuffoloDirector, since June 2023
• Allen NissensonDirector+$10.9K
• Karen J WilsonDirector
• Jay VenkatesanDirector+$1.15M-$2.55M
• Christopher HaqqOfficer, since June 2023
• Peter DeMuthChief Scientific Officer, since June 2023
• Preetam ShahOfficer, since March 2025
• Robert ConnellyCEO, President and Director, since June 2023
• Brian PiekosChief Financial Officer, since June 2023
• Assaf SegalDirector, since June 2023
• Annette MatthiesOfficer, since June 2023
• Itzhak GoldbergDirector-$1.15M
• Victor F GanziDirector-$3.95M
• Gilbert S OmennDirector
• John F. NeylanOfficer-$22.1K
• Jennifer J RhodesOfficer-$38.5K
• Gregory S CurhanOfficer+$9,480
• Eisa-Abc LLC10% owner, since February 2021

Recent Form 3, 4, and 5 filings for ELTX

• 69d
  SEC Form 4 filed by Director Adams Julian

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Ashe Carol Gail

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Nissenson Allen

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Ruffolo Robert R

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Wilson Karen J

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 69d
  SEC Form 4 filed by Director Venkatesan Jay

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 116d
  SEC Form 4 filed by Officer Haqq Christopher

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 116d
  SEC Form 4 filed by Chief Scientific Officer Demuth Peter

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 116d
  SEC Form 4 filed by CEO, President and Director Connelly Robert

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 116d
  SEC Form 4 filed by Officer Shah Preetam

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 280d
  CEO, President and Director Connelly Robert was granted 73,600 shares, increasing direct ownership by 157% to 120,570 units (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 280d
  Officer Shah Preetam was granted 24,000 shares (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 280d
  Chief Scientific Officer Demuth Peter was granted 20,800 shares, increasing direct ownership by 2,799% to 21,543 units (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 280d
  Officer Haqq Christopher was granted 25,400 shares, increasing direct ownership by 79% to 57,381 units (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 335d
  Chief Scientific Officer Demuth Peter exercised 362 shares at a strike of $4.41, increasing direct ownership by 95% to 743 units (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 524d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Ashe Carol Gail

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Nissenson Allen

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Venkatesan Jay

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Adams Julian

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Wilson Karen J

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Ruffolo Robert R

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 539d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 573d
  SEC Form 4 filed by Officer Shah Preetam

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 587d
  SEC Form 3 filed by new insider Shah Preetam

  3 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 613d
  Director Chudnovsky Yekaterina converted options into 3,500,573 shares (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 644d
  SEC Form 4 filed by Chief Scientific Officer Demuth Peter

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 644d
  SEC Form 4 filed by Officer Haqq Christopher

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 644d
  SEC Form 4 filed by CEO, President and Director Connelly Robert

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 677d
  Amendment: SEC Form 4 filed by Director Venkatesan Jay

  4/A - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 692d
  Chief Scientific Officer Demuth Peter exercised 381 shares at a strike of $4.41 (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 711d
  Director Venkatesan Jay exercised 50,000 in-the-money shares at a strike of $0.01, increasing direct ownership by 39% to 179,581 units (SEC Form 4)

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Wilson Karen J

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Adams Julian

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Ashe Carol Gail

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Venkatesan Jay

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Ruffolo Robert R

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 715d
  SEC Form 4 filed by Director Nissenson Allen

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 769d
  SEC Form 4 filed by CEO, President and Director Connelly Robert

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 769d
  SEC Form 4 filed by Chief Scientific Officer Demuth Peter

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 769d
  SEC Form 4 filed by Officer Haqq Christopher

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 818d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 860d
  SEC Form 4 filed by Director Venkatesan Jay

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 861d
  SEC Form 4 filed by Director Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
• 965d
  SEC Form 4 filed by Chudnovsky Yekaterina

  4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)